Daily Rules, Proposed Rules, and Notices of the Federal Government
Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on August 20, 2012, Fisher Clinical Services, Inc., 7554 Schantz Road,
The company plans to import the listed controlled substance to conduct clinical trials.
Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance listed in schedule II, which falls under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR SS 1301.43 and in such form as prescribed by 21 CFR SS 1316.47.
Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 10, 2012.
This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR SS 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the